# Omecamtiv PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/omecamtiv

> Omecamtiv, sponsored by CYTOKINETICS INC (CYTK), received a complete response letter from the FDA; the decision is dated February 28, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is omecamtiv FDA approved?

Not as of November 16, 2026. Omecamtiv, sponsored by CYTOKINETICS INC (CYTK), received a complete response letter from the FDA; the decision is dated February 28, 2023. SEC Form 10-Q: "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." [Calendar and source filings](https://sec-api.dev/pdufa/omecamtiv)

Source: SEC Form 10-Q, accession 0001193125-25-267059, https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm (retrieved 2026-11-12). Last confirmed 2026-05-05. Cite: https://sec-api.dev/pdufa/omecamtiv#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | omecamtiv |
| Codes |  |
| Sponsor | CYTOKINETICS INC (CYTK) https://sec-api.dev/companies/cytk/catalysts |
| Indications | chronic heart failure with hfref, chronic heart failure with hfref, and in march 2023, we |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### February 28, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Stage: 3. Indication: chronic heart failure with HFrEF.
- First seen 2025-02-27, last confirmed 2026-05-05.
- SEC Form 10-Q (accession 0001193125-25-267059): "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105108): "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000095017025105108/cytk-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-064529): "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064529/cytk-20250331.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "For example, the CRL we received in February 2023 in connection with our NDA for omecamtiv mecarbil stated that the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and in March 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm
- SEC Form 10-K (accession 0001193125-26-076495): "For example, the CRL we received in February 2023 in connection with our NDA for omecamtiv mecarbil stated that the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and in March 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- SEC Form 10-K (accession 0000950170-25-029206): "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/omecamtiv.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Omecamtiv PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/omecamtiv

```bibtex
@misc{secapidev_pdufa_omecamtiv_20261116,
  title        = {Omecamtiv PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/omecamtiv}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_omecamtiv_20261116","title":"Omecamtiv PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/omecamtiv","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
